NeoGenomics validates and launches new detection test for the CALR gene NeoGenomics announced that it has validated and launched a new test for the detection of mutations in the calreticulin, or CALR, gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms for the first time at the annual meeting of the American Society of Hematology last month. Since then, findings on the CALR gene have been published in the three articles referenced below.
News For NEO From The Last 14 Days
Check below for free stories on NEO the last two weeks.